Leukemia and Lymphoma Program

Clinical

Young adult cancers; acute myeloid & lymphoid leukemia; Hodgkin lymphoma; new anticancer therapy development

Research

Molecular etiology and pharmacogenetics of pediatric cancers; Down syndrome-associated leukemia; new anticancer drug development

Biography

John P. Perentesis, MD, is a nationally recognized expert in the development of new drugs and molecular therapies for pediatric and young adult cancers and leukemia. His laboratory has developed novel anticancer drugs, and discovered genes important in the growth of normal and malignant cells. His laboratory is also developing the use of tumor and patients genetics research for personalizing therapies. In clinical research, he serves in leadership roles for the National Cancer Institute’s Investigational Drug Steering Committee and the NCI Pediatric Phase I Consortium.

In 2010, Dr. Perentesis was elected by pediatric oncologists from across the country to the national Executive Committee for the NCI-funded Children’s Oncology Group (COG). The COG is the world's largest, cooperative children's cancer research entity. He also is in leadership efforts in the COG for new therapies for leukemia, and adolescent and young adult cancers.

Dr. Perentesis has been elected by his peers for inclusion in the Best Doctors in America List from 1998 to 2016.

MD: University of Michigan, Ann Arbor, MI, 1980.

Residency: University of Minnesota Medical School, Minneapolis, MN, 1983.

Fellowship: University of Minnesota Medical School, Minneapolis, MN, 1986.

Postdoctoral: University of Minnesota Medical School, Minneapolis, MN, 1986.

Certification: Pediatrics, 1989; Hematology/Oncology, 1990.

Dorris K, Fouladi M, Davies SM, Perentesis JP, Lawrence JM, Chow LM, Assa'ad A, Uygungil B, Jodele S. . Severe Allergic Reactions to Thiol-based Cytoprotective Agents Mesna and Amifostine in a Child With a Supratentorial Primitive Neuroectodermal Tumor. J Pediatr Hematol Oncol. 2011 Jun 3.

Davies SM, Perentesis JP. Tribute: the American Society of Pediatric Hematology/Oncology (ASPHO), 2011 Distinguished Career Award goes to Dr. William G. Woods. Pediatr Blood Cancer. 2011 Jun;56(6):895-6.

Phillips CL, Gerbing R, Alonzo T, Perentesis JP, Harley IT, Meshinchi S, Bhatla D, Radloff G, Davies SM. MDM2 polymorphism increases susceptibility to childhood acute myeloid leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2010 Aug;55(2):248-53.

Wagner LM, Perentesis JP, Reid JM, Ames MM, Safgren SL, Nelson MD Jr, Ingle AM, Blaney SM, Adamson PC. Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: a Children's Oncology Group phase I consortium study. Pediatr Blood Cancer. 2010 Apr;54(4):538-45.

Mehta PA, Gerbing RB, Alonzo TA, Elliott JS, Zamzow TA, Combs M, Stover E, Ross JA, Perentesis JP, Meschinchi S, Lange BJ, Davies SM. FAS promoter polymorphism: outcome of childhood acute myeloid leukemia. A children's oncology group report. Clin Cancer Res. 2008 Dec 1;14(23):7896-9.

Bhatla D, Gerbing RB, Alonzo TA, Conner H, Ross JA, Meshinchi S, Zhai X, Zamzow T, Mehta PA, Geiger H, Perentesis J, Davies SM. Cytidine deaminase genotype and toxicity of cytosine arabinoside therapy in children with acute myeloid leukemia. Br J Haematol. 2009 Feb;144(3):388-94.

Geller JI, Wall D, Perentesis J, Blaney SM, Bernstein M; Pediatric Oncology Group study 9376. Phase I study of paclitaxel with standard dose ifosfamide in children with refractory solid tumors: a Pediatric Oncology Group study (POG 9376). Pediatr Blood Cancer. 2009 Mar;52(3):346-50.

Johansson G, Mahller YY, Collins MH, Kim MO, Nobukuni T, Perentesis J, Cripe TP, Lane HA, Kozma SC, Thomas G, Ratner N. Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors. Mol Cancer Ther. 2008 May;7(5):1237-45.

Bhatla D, Gerbing RB, Alonzo TA, Mehta PA, Deal K, Elliott J, Meshinchi S, Geiger H, Perentesis JP, Lange BJ, Davies SM; Children's Oncology Group. DNA repair polymorphisms and outcome of chemotherapy for acute myelogenous leukemia: a report from the Children's Oncology Group. Leukemia. 2008 Feb;22(2):265-72.

Mo J, Lampkin B, Perentesis J, Poole L, Bao L. Translocation (8;18;16)(p11;q21;p13). A new variant of t(8;16)(p11;p13) in acute monoblastic leukemia: case report and review of the literature. Cancer Genet Cytogenet. 2006 Feb;165(1):75-8. Review.

Oncology

Michael J. Absalon, MD, PhD Director, Medical Education Program 513-517-2234 michael.absalon@cchmc.org

Karen C. Burns, MD, MS Co-Director, Comprehensive Fertility Care and Preservation Program 513-517-2234 karen.burns@cchmc.org

Adrienne M. Hammill, MD, PhD Research Director, Hemangioma & Vascular Malformation Program 513-517-2234 adrienne.hammill@cchmc.org

High Res

Adrienne M. Hammill, MD, PhD

Research Director, Hemangioma & Vascular Malformation Program

Academic Affiliations

Assistant Professor, UC Department of Pediatrics

Phone 513-517-2234

Fax 513-636-6612

Email adrienne.hammill@cchmc.org

Show All

Clinical Interests

Hemangiomas and vascular malformations; genetic predispositions to cancer

Biography

Dr. Adrienne M. Hammill is trained in pediatrics and hematology/oncology and is particularly interested in bringing new and/or better medical therapy options to the treatment of vascular anomalies. She is one of the medical physicians for the Hemangioma and Vascular Malformations team. She obtained her schooling at the University of Texas Southwestern and completed her residency and fellowship here at Cincinnati Children’s Hospital Medical Center. She is a dedicated professional and strives to improve the treatment for her patients. Cincinnati Children’s has been named a site for the brain vascular malformations consortium, which is a clinical research group funded by National Institutes of Health and the rare disease network and more recently a SWF Center of Excellence. She has developed a broader interest in Brain Vascular Malformations, and now heads our HHT Center and participates in the Cerebrovascular Clinic housed in Neurosurgery as well.

MD: University of Texas Southwestern Medical School, Dallas, TX, 2004.

PhD: University of Texas Southwestern Graduate School of Biomedical Sciences, Dallas, TX, 2004.

Residency: Cincinnati Children’s Hospital Medical Center, Cincinnati, OH.

Fellowship: Cincinnati Children’s Hospital Medical Center.

Certifications: Pediatrics, 2008; Pediatric Hematology Oncology, 2011.

Maureen M. O'Brien, MD, MS Medical Director, Leukemia/Lymphoma Program 513-803-1678 maureen.obrien@cchmc.org

Christine L. Phillips, MD Member, Division of Oncology 513-803-3216 christine.phillips@cchmc.org

High Res

Christine L. Phillips, MD

Member, Division of Oncology

Academic Affiliations

Assistant Professor, UC Department of Pediatrics

Phone 513-803-3216

Fax 513-636-3549

Email christine.phillips@cchmc.org

Show All

Specialties

Leukemia and lymphoma; leukemia pharmacogenetics; translational and clinical development of new drugs for high-risk and relapsed leukemias

Biography

Christine Phillips, MD, is an oncologist with a clinical focus on leukemia and lymphoma and a clinical and translational research focus on the development of novel therapies for pediatric leukemia and in leukemia pharmacogenetics.

Dr. Phillips earned her undergraduate degree in biochemistry and her medical degree from Indiana University, completed her residency in pediatrics at Children’s Memorial Hospital in Chicago, and her fellowship in pediatric hematology/oncology at Cincinnati Children’s, where she was co-chief fellow. She was a 2008 Hyundai Hope on Wheels Foundation Scholar.

MD: Indiana University School of Medicine, Indianapolis, IN, 2002.

Residency: Pediatrics, Children’s Memorial Hospital, Chicago, IL, 2005.

Fellowship: Pediatric Hematology/Oncology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 2010.

Certification: Pediatrics, 2005; Pediatric Hematology/Oncology, 2011.

Dixon S, Lane A, O’Brien MO, Burns KC, Mangino JL, Breese EH,Absalon M, Perentesis JP, Phillips CL. Viral surveillance using PCR during treatment of AML and ALL. Pediatric Blood and Cancer. 2017.

Fouladi M, Perentesis JP, Phillips CL, Leary S, Reid JM, McGovern, R, Ingle AM, Ahern CH, Ames MM, Houghton P, Doyle LA, Weigel B, Blaney SM. A phase I trial of MK-2206 in children with refractory malignancies: A Children’s Oncology Group Study. Pediatr Blood Cancer. 2014 Jul;61(7):1246-51.

Phillips CL, Davies SM, McMasters R, Absalon M, O’Brien M, Mo J, Broun R, Moscow JA, Smolarek T, Garzon R, Blum W, Schwind, Marcucci G, Perentesis JP. Low dose decitabine in very high risk relapsed or refractory acute myeloid leukemia in children and young adults. British Journal of Haematology. 2013;161(3):406-10.

Phillips CL, Miles L, Jones BV, Sutton M, Crone K, Fouladi M. Medulloblastoma with melanotic differentiation: Case report and review of the literature. J Neurooncol. 2011 Jul;103(3):759-64.

Phillips CL, Gerbing R, Alonzo T, Perentesis JP, Harley ITW, Meshinchi S, Bhatla D, Radloff G, Davies SM. MDM2 polymorphism increases susceptibility to childhood acute myeloid leukemia. Pediatr Blood Cancer. 2010 Aug;55(2):248-53.

Blood and Marrow Transplant

Jacob (Jack) J.H. Bleesing, MD, PhD Co-Director, Diagnostic Immunology Laboratories 513-517-2234 jack.bleesing@cchmc.org

Stella M. Davies, MBBS, PhD, MRCP Director, Division of Bone Marrow Transplantation and Immune Deficiency 513-636-1371 stella.davies@cchmc.org

High Res

Stella M. Davies, MBBS, PhD, MRCP

Director, Division of Bone Marrow Transplantation and Immune Deficiency

Institute Co-Director, Cancer and Blood Diseases Institute

Jacob G. Schmidlapp Endowed Chair

Academic Affiliations

Professor, UC Department of Pediatrics

Phone 513-636-1371

Fax 513-803-1969

Email stella.davies@cchmc.org

Show All

Visit the Davies Lab.

Biography

Dr. Davies has been elected by peers for inclusion in the Best Doctors in America List.

MBBS: University of Newcastle-Upon-Tyne, England, 1981.

Clinical and Fellowship Training: The Royal Victoria Infirmary, Newcastle General Hospital and Great Ormond St. Hospital, 1981 to 1985.

PhD: University of Newcastle-Upon-Tyne, England, 1989.

Pediatric Fellowship: University of Minnesota, Minneapolis, MN, 1989 to 1993.

Mehta PA, Harris RE, Davies SM, Kim MO, Mueller R, Lampkin B, Mo J, Myers K, Smolarek TA. Numerical chromosomal changes and risk of development of myelodysplastic syndrome -- acute myeloid leukemia in patients with Fanconi anemia. Cancer Genet Cytogenet. 2010 Dec;203(2):180-6.

Jodele S, Bleesing JJ, Mehta PA, Filipovich AH, Laskin BL, Goebel J, Pinkard SL, Davies SM. Successful early intervention for hyperacute transplant-associated thrombotic microangiopathy following pediatric hematopoietic stem cell transplantation. Pediatr Transplant. 2010 Nov 5.

Marsh RA, Vaughn G, Kim MO, Li D, Jodele S, Joshi S, Mehta PA, Davies SM, Jordan MB, Bleesing JJ, Filipovich AH. Reduced-intensity conditioning significantly improves survival of patients with hemophagocytic lymphohistiocytosis undergoing allogeneic hematopoietic cell transplantation. Blood. 2010 Dec 23;116(26):5824-31.

Laskin BL, Goebel J, Davies SM, Khoury JC, Bleesing JJ, Mehta PA, Filipovich AH, Paff ZN, Lawrence JM, Yin HJ, Pinkard SL, Jodele S. Early clinical indicators of transplant-associated thrombotic microangiopathy in pediatric neuroblastoma patients undergoing auto-SCT. Bone Marrow Transplant. 2010 Aug 9.

Phillips CL, Gerbing R, Alonzo T, Perentesis JP, Harley IT, Meshinchi S, Bhatla D, Radloff G, Davies SM. MDM2 polymorphism increases susceptibility to childhood acute myeloid leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2010 Aug;55(2):248-53.

Mehta PA, Vinks AA, Filipovich A, Bleesing J, Jodele S, Jordan MB, Marsh R, Tarin R, Edwards S, Fearing D, Lawrence J, Davies SM. Alternate-day micafungin antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic study. Biol Blood Marrow Transplant. 2010 Oct;16(10):1458-62.

Sakagami T, Beck D, Uchida K, Suzuki T, Carey BC, Nakata K, Keller G, Wood RE, Wert SE, Ikegami M, Whitsett JA, Luisetti M, Davies S, Krischer JP, Brody A, Ryckman F, Trapnell BC. Patient-derived granulocyte / macrophage colony-stimulating factor autoantibodies reproduce pulmonary alveolar proteinosis in nonhuman primates. Am J Respir Crit Care Med. 2010 Jul 1;182(1):49-61.

Wang D, Zhang W, Kalfa TA, Grabowski G, Davies S, Malik P, Pan D. Reprogramming erythroid cells for lysosomal enzyme production leads to visceral and CNS cross-correction in mice with Hurler syndrome. Proc Natl Acad Sci U S A. 2009 Nov 24;106(47):19958-63.

Davies SM, Wang D, Wang T, Arora M, Ringden O, Anasetti C, Pavletic S, Casper J, Macmillan ML, Sanders J, Wall D, Kernan NA. Recent decrease in acute graft-versus-host disease in children with leukemia receiving unrelated donor bone marrow transplants. Biol Blood Marrow Transplant. 2009 Mar;15(3):360-6.

Myers KC, Davies SM. Hematopoietic stem cell transplantation for bone marrow failure syndromes in children. Biol Blood Marrow Transplant. 2009 Mar;15(3):279-92. Review.

Michael B. Jordan, MD Member, Division of Bone Marrow Transplantation and Immune Deficiency 513-636-7287 michael.jordan@cchmc.org

Parinda A. Mehta, MD Member, Division of Bone Marrow Transplantation and Immune Deficiency 513-636-4913 parinda.mehta@cchmc.org

Therapeutic Nuclear Medicine

Michael J. Gelfand, MD 513-636-7650 michael.gelfand@cchmc.org

Michael J. Gelfand, MD

Academic Affiliations

Professor, UC Department of Radiology

UC Department of Pediatrics

Phone 513-636-7650

Fax 513-636-8145

Email michael.gelfand@cchmc.org

Show All

Specialties

Nuclear medicine

Biography

Michael J. Gelfand, MD, received his BA from the University of Michigan and his MD from Stanford University. After two years at the National Institutes of Health, he completed residencies in pediatrics at Cincinnati Children's and nuclear medicine at the University of Cincinnati Medical Center.

Dr. Gelfand's research interests include I-123-MIBG imaging of neuroblastoma, new applications of hybrid imaging (PET/CT, SPECT/CT, PET/MRI) in pediatrics, and radiation dose reduction in nuclear medicine and hybrid imaging.

Dr. Gelfand has served as president of the Society of Nuclear Medicine, and served on the board of directors of that organization for 10 years.

Dr. Gelfand co-edited the textbooks Effective Use of Computers in Nuclear Medicine and Pediatric Nuclear Imaging. His publications include 126 journal articles and 31 book chapters. He has been an invited lecturer or visiting professor in France, Germany, the Netherlands, Italy, Argentina, Brazil, Japan and Australia.

BA: University of Michigan, Ann Arbor, MI, 1966.

MD: Stanford University, Stanford, CA, 1971.

Residency: Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 1973-1975, 1977; Nuclear Medicine, University of Cincinnati, Cincinnati, OH, 1975-1977.

Certification: Pediatrics, 1978; Nuclear Medicine, 1978.

Gelfand MJ, Parisi MT, Treves ST. Pediatric Radiopharmaceutical Administered Doses: 2010 North American Consensus Guidelines. J Nucl Med. 2011 Jan 13.

Seo JH, Holland K, Rose D, Rozhkov L, Fujiwara H, Byars A, Arthur T, Degrauw T, Leach JL, Gelfand MJ, Miles L, Mangano FT, Horn P, Lee KH. Multimodality imaging in the surgical treatment of children with nonlesional epilepsy. Neurology. 2011 Jan 4;76(1):41-8.

Wagner LM, Gelfand MJ, Laor T, Ryckman FC, Al-Ghawi H, Bove KE. A Welcome Surprise: Nodular Fasciitis Presenting as Soft Tissue Sarcoma. J Pediatr Hematol Oncol. 2010 Oct 21.

Gelfand MJ. Dose reduction in pediatric hybrid and planar imaging. Q J Nucl Med Mol Imaging. 2010 Aug;54(4):379-88.

Sharp SE, Shulkin BL, Gelfand MJ, Salisbury S, Furman WL. 123I-MIBG scintigraphy and 18F-FDG PET in neuroblastoma. J Nucl Med. 2009 Aug;50(8):1237-43.

Young LR, Franz DN, Nagarkatte P, Fletcher CD, Wikenheiser-Brokamp KA, Galsky MD, Corbridge TC, Lam AP, Gelfand MJ, McCormack FX. Utility of [18F]2-fluoro-2-deoxyglucose-PET in sporadic and tuberous sclerosis-associated lymphangioleiomyomatosis. Chest. 2009 Sep;136(3):926-33.

Gelfand MJ. Dosimetry of FDG PET/CT and other molecular imaging applications in pediatric patients. Pediatr Radiol. 2009 Feb;39 Suppl 1:S46-56

Gelfand MJ, Gruppo RA, Nasser MP. Ventilation-perfusion scintigraphy in children and adolescents is associated with a low rate of indeterminate studies. Clin Nucl Med. 2008 Sep;33(9):606-9.

Gelfand MJ, Lemen LC. PET/CT and SPECT/CT dosimetry in children: the challenge to the pediatric imager. Semin Nucl Med. 2007 Sep;37(5):391-8. Review.

Wu SW, Graham B, Gelfand MJ, Gruppo RE, Dinopolous A, Gilbert DL. Clinical and positron emission tomography findings of chorea associated with primary antiphospholipid antibody syndrome. Mov Disord. 2007 Sep 15;22(12):1813-5.

Neurology

Mary Sutton, MD Pediatric Neuro-oncologist, Division of Neurology 513-636-4222

Physical Medicine and Rehabilitation

David W. Pruitt, MD Medical Director, Inpatient Pediatric Rehabilitation Unit 513-636-7480 david.pruitt@cchmc.org

High Res

David W. Pruitt, MD

Medical Director, Inpatient Pediatric Rehabilitation Unit

Director, Pediatric Rehabilitation Medicine Fellowship

Academic Affiliations

Associate Professor, UC Department of Pediatrics

UC Department of Neurology and Rehabilitation Medicine

Phone 513-636-7480

Fax 513-636-7360

Email david.pruitt@cchmc.org

Show All

Clinical

Inpatient pediatric rehabilitation; pediatric cancer rehabilitation; pediatric neuro-oncology

Research

Functional outcomes of children with brain tumors

BS: University of Notre Dame, Notre Dame, IN, 1994.

MD: Loyola University Stritch School of Medicine, Chicago, IL, 1998.

Residency: Pediatrics, Cincinnati Children's Hospital Medical Center; Physical Medicine and Rehabilitation, University of Cincinnati, Cincinnati, OH.

Certification: Physical Medicine and Rehabilitation, recertification 2014; Pediatric Rehabilitation Medicine, recertification 2014.

Visscher M, King A, Nie AM, Schaffer P, Taylor T, Pruitt D et al. A quality improvement collaborative project to reduce pressure ulcers in PICUs. Pediatrics. 2013: 131(6): e1950-60.

Pruitt DW, Ayyangar R, Craig K, White A, Neufeld JA. Pediatric brain tumor rehabilitation. J Pediatr Rehabil Med. 2011; 4(1): 59-70.

Pruitt DW, Tsai T. Common Comorbidities Associated With Cerebral Palsy. In: LJ Michaud (ed.): Physical Medicine and Rehabilitation Clinics of North America, 2009; 20(3):453-67.

Endocrinology and Fertility

Meilan M. Rutter, MD Member, Division of Endocrinology 513-636-4744 meilan.rutter@cchmc.org

High Res

Meilan M. Rutter, MD

Member, Division of Endocrinology

Academic Affiliations

Associate Professor, UC Department of Pediatrics

Phone 513-636-4744

Fax 513-636-7486

Email meilan.rutter@cchmc.org

Show All

Clinical

Bone health and calcium metabolism; disorders of growth, puberty and sex development; endocrine function in cancer survivors; endocrine function in neuromuscular disorders

Research

Insulin-like growth factor-1 (IGF-1) therapy in Duchenne muscular dystrophy

Biography

Meilan Rutter is board-certified in pediatrics and pediatric endocrinology. She is an associate professor of pediatrics in the Division of Endocrinology, and joined the faculty of Cincinnati Children's Hospital Medical Center within the UC College of Medicine in 2008. Currently, Dr. Rutter is assistant director of the Pediatric Endocrinology Fellowship Program.

Dr. Rutter received her degrees of Bachelor of Medicine and Bachelor of Surgery (MB, BCh) from the University of Wales College of Medicine. She completed her training in pediatrics in New Zealand, and was admitted to Fellowship of the Royal Australasian College of Physicians (FRACP) in 1995. She underwent fellowship training in pediatric endocrinology at Cincinnati Children's. She completed further pediatric residency training to achieve American Board of Pediatrics specialty and subspecialty board certification.

Dr. Rutter treats children and adolescents with endocrine disorders and diabetes mellitus. She serves as a consultant for the Neuromuscular Comprehensive Care Center and the Neuro-Oncology Program at Cincinnati Children's. Additionally, she is a member of the Disorders of Sex Development Center's interdisciplinary team.

MB, BCh: University of Wales College of Medicine, Cardiff, United Kingdom.

FRACP: Royal Australasian College of Physicians, New Zealand.

Residency: Auckland Children's Hospital and Dunedin Hospital, New Zealand; Cincinnati Children's, Cincinnati, OH.

Fellowship: Pediatric Endocrinology, Cincinnati Children's, Cincinnati, OH.

Certification: General Pediatrics, American Board of Pediatrics, 2002; Pediatric Endocrinology, American Board of Pediatrics, 2003; Pediatrics, Fellowship of the Royal Australasian College of Physicians, 1995.

Rose SR, Rutter MM, Mueller R, Harris M, Hamon B, Fletcher Bulluck A, Smith FO. Bone mineral density is normal in children with Fanconi anemia. Pediatr Blood Cancer. 2011 Dec 1;57(6):1034-8.

Bianchi ML, Biggar D, Bushby K, Rogol AD, Rutter MM, Tseng B. Endocrine aspects of Duchenne Muscular Dystrophy. Neuromuscul Disord. 2011 Apr;21(4):298-303.

Wong BL, Rutter MM, Rose SR, Clark E, Vonderhaar K. Growth hormone therapy in Duchenne Muscular Dystrophy. Best Evidence Statement, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio. 2009.

Rutter MM. What is an endocrinologist and why is endocrine care important for Duchenne? Action Duchenne newsletter. 2009.

Murray R, Rutter MM, Racine M, Rose SR. Report on The Endocrine Society’s 90^th Annual Meeting. Highlights. 2008;16(4):1-36.

Rutter MM, Racine M, Rose SR. Report on The Endocrine Society’s 89^th Annual Meeting. Highlights. 2007;15(3):2-30.

Rutter MM, Rose SR. Long-term endocrine sequelae of childhood cancer. Curr Opin Pediatr. 2007 Aug;19(4):480-7.

Rutter MM, Markoff E, Clayton L, Akeno N, Zhao G, Clemens TL, Chernausek SD. Osteoblast-specific expression of insulin-like growth factor-1 in bone of transgenic mice induces insulin-like growth factor binding protein-5. Bone. 2005 Feb;36(2):224-31.

Rutter MM, Prahalad S, Passo M, Backeljauw PF. Idiopathic hypercalcemia and eosinophilic fasciitis: a novel association. J Pediatr Endocrinol Metab. 2004 Sep;17(9):1251-4.

Rutter MM, Smith EP. Pseudohypoparathyroidism type Ia: late presentation with intact mental development. J Bone Miner Res. 1998 Jul;13(7):1208-9.

Hematopathology

Pain Management and Palliative Care

Kenneth R. Goldschneider, MD, FAAP Director, Pain Management Center 513-636-7768 kenneth.goldschneider@cchmc.org

High Res

Kenneth R. Goldschneider, MD, FAAP

Director, Pain Management Center

Academic Affiliation

Professor

Phone 513-636-7768

Fax 513-636-2920

Email kenneth.goldschneider@cchmc.org

Show All

Clinical

Complex chronic pain conditions in infants, children and young adults, including those related to vascular malformations, epidermolysis bullosa and cancer.

Research

Outcomes of pain treatment, with a focus on outpatient, chronic pain management.

MD: University of Connecticut Health Center School of Medicine, Farmington, CT, 1991.

Residency: Pediatrics, Duke University Medical Center, Durham, NC, 1991 - 1994; Anesthesiology, University of Pittsburgh Medical Center, Pittsburgh, PA, 1994-1997.

Fellowship: Pediatric Anesthesia, Children's Hospital of Pittsburgh, Pittsburgh, PA, 1997 - 1998; Pain Management, Longwood Combined Pain Fellowship, The Children's Hospital, Boston, MA, 1998-1999.

Certification: American Board of Pediatrics, 1994; American Board of Anesthesiology, 1998; ABA Pain Management, 2000.

Lynch-Jordan AM, Kashikar-Zuck S, Goldschneider KR. Parent perceptions of adolescent pain expression: the adolescent pain behavior questionnaire. Pain. 2010 Dec;151(3):834-42.

Goldschneider K, Lucky AW, Mellerio JE, Palisson F, del Carmen Viñuela Miranda M, Azizkhan RG. Perioperative care of patients with epidermolysis bullosa: proceedings of the 5th international symposium on epidermolysis bullosa, Santiago Chile, December 4-6, 2008. Paediatr Anaesth. 2010 Sep;20(9):797-804.

Goldschneider KR, Lucky AW. Pain management in epidermolysis bullosa. Dermatol Clin. 2010 Apr;28(2):273-82, ix. Review.

Meyer MJ, Goldschneider KR, Bielefeldt K, Zeltzer L, Lackner J, Keefer L. Functional abdominal pain in adolescence: a biopsychosocial phenomenon. J Pain. 2008 Nov;9(11):984-90.

Hosu L, Meyer MJ, Goldschneider KR. Cerebrospinal fluid cutaneous fistula after epidural analgesia in a child. Reg Anesth Pain Med. 2008 Jan-Feb;33(1):74-6.

Goldschneider KR, Racadio JM, Weidner NJ. Celiac plexus blockade in children using a three-dimensional fluoroscopic reconstruction technique: case reports. Reg Anesth Pain Med. 2007 Nov-Dec;32(6):510-5.

Lynch AM, Kashikar-Zuck S, Goldschneider KR, Jones BA. Sex and age differences in coping styles among children with chronic pain. J Pain Symptom Manage. 2007 Feb;33(2):208-16.

Lynch AM, Kashikar-Zuck S, Goldschneider KR, Jones BA. Psychosocial risks for disability in children with chronic back pain. J Pain. 2006 Apr;7(4):244-51.

Kashikar-Zuck S, Vaught MH, Goldschneider KR, Graham TB, Miller JC. Depression, coping, and functional disability in juvenile primary fibromyalgia syndrome. J Pain. 2002 Oct;3(5):412-9.

Kashikar-Zuck S, Goldschneider KR, Powers SW, Vaught MH, Hershey AD. Depression and functional disability in chronic pediatric pain. Clin J Pain. 2001 Dec;17(4):341-9.

Mark Meyer, MD Medical Director, Pediatric Palliative and Comfort Care Team 513-636-4408 mark.meyer@cchmc.org

High Res

Mark Meyer, MD

Medical Director, Pediatric Palliative and Comfort Care Team

Anesthesiologist, Department of Anesthesia

Academic Affiliation

Associate Professor

Phone 513-636-4408

Fax 513-636-2920

Email mark.meyer@cchmc.org

Show All

Clinical

Palliative medicine; end of life care; anesthesiology; pain management

Research

Anesthesia; pain management

Biography

Mark Meyer, MD, is a board-certified anesthesiologist who completed his residency at the Cleveland Clinic in Cleveland, Ohio.

Dr. Meyer joined the Department of Anesthesia in 2003 following his Pediatric Anesthesia Fellowship at Cincinnati Children's Hospital Medical Center.

Dr. Meyer is a staff anesthesiologist, as well as an attending physician in the Division of Pain Management, caring for patients with acute pain. In addition, Dr. Meyer is an attending physician for StarShine Hospice, the pediatric hospice at Cincinnati Children's.

In 2006, Dr. Meyer received his board certification from the American Board of Hospice and Palliative Medicine. He has been an integral part of the development and implementation of the Pediatric Palliative and Comfort Care Team / PACT at Cincinnati Children's.

Dr. Meyer is the PACT consulting physician, partnering with families in order to offer a range of comprehensive, family-centered care for children with chronic, complex or life-threatening conditions.

MD: University of Cincinnati College of Medicine, Cincinnati, OH, 1998.

Residency: Cleveland Clinic Foundation, Cleveland, OH, 2002.

Fellowship: Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2003.

Certification: Anesthesiology, 2004; Hospice and Palliative Medicine, 2006.

Norbert J. Weidner, MD Anesthesiologist, Department of Anesthesia 513-636-4408 norbert.weidner@cchmc.org

High Res

Norbert J. Weidner, MD

Anesthesiologist, Department of Anesthesia

Academic Affiliation

Associate Professor

Phone 513-636-4408

Fax 513-636-2920

Email norbert.weidner@cchmc.org

Show All

Clinical Interests

Pediatric palliative care; pediatric anesthesia

Biography

Norbert J. Weidner, MD, is a board-certified pediatrician as well as a board-certified anesthesiologist. Following training in pediatrics Cincinnati Children's Hospital Medical Center, as well as Dayton Children's Hospital, he pursued a fellowship in pediatric anesthesia/critical care/regional anesthesia in Melbourne, Australia, for one year.

Upon completion of his fellowship in 1988, Dr. Weidner joined the Department of Anesthesia at Cincinnati Children's. In addition to his staff duties as an anesthesiologist, Dr. Weidner was an attending staff in the pediatric intensive care unit for approximately two years.

To incorporate the fellowship training he received in Australia, Dr. Weidner began the pain management group at Cincinnati Children's. He has participated in the pain management group both in the care of acute postoperative pain as well as chronic pain management.

In 2004, Dr. Weidner received board certification with the American Board for Hospice and Palliative Medicine. Dr. Weidner has been affiliated with the hospice service at Cincinnati Children's since its inception and currently serves as StarShine Hospice's medical director.

Dr. Weidner is passionate about partnering with families to offer a range of comprehensive, family-centered care to children with chronic, complex or life-threatening conditions. His vision to address the needs of this patient population resulted in the development of the Pediatric Palliative and Comfort Care Team (PACT) here at Cincinnati Children's. Dr. Weidner serves as the director of this consulting service.

MD: Temple Medical School, Philadelphia, PA, 1975.

Residency: Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 1975-77; Pediatrics, Dayton Children's Hospital, Dayton, OH 1981-82; Anesthesia, University of Cincinnati College of Medicine, Cincinnati, OH, 1985-87.

Fellowship: Pediatric Anesthesia, Royal Children's Hospital, Melbourne, Australia, 1988.

Certification: American Board of Anesthesiology, 1983; American Board of Pediatrics, 1989; Diplomat, American Board Medical Acupuncture, 2001; Hospice and Palliative Medicine, 2004.

Henderson C, Fitzgerald M, Weidner NJ, Hoehn S. Pediatrician Ambiguity in Understanding Palliative Sedation at the End of Life. Am J Hosp Palliat Care. 2015 Oct 5.

Benoit S, Antommaria AH, Weidner N, Lorts A. Difficult decision: What should we do when a VAD-supported child experiences a severe stroke? Pediatr Transplant. 2015 Mar;19(2):139-43.

Klick JC, Friebert S, Hutton N, Osenga K, Pituch KJ, Vesel T, Weidner NJ, Block SD, Morrison LJ, and on behalf of the American Board of Hospice and Palliative Medicine Competencies Work Group. Pediatrics: Developing Competencies for Pediatric Hospice and Palliative Medicine. Pediatrics. 2014 Dec;134(6):e1670-7.

Weidner NJ, Plantz D. Ethical Considerations in the Management of Analgesia in Terminally Ill Pediatric Patients. Journal of Pain and Symptom Management. 2014;(48)5:998-1003.

Weidner NJ, Cameron M, et al. End-of-Life Care for the Dying Child: What matters most to parents. Journal of Palliative Care. 2011;(27)4:279-286.

Goldschneider KR, Weidner NJ, Racadio JM. Celiac Plexus Blockade in Children Using a 3-D Fluoroscopic Reconstruction Technique. Reg Anes Pain Manage. 2007;32:510-15.

Weidner NJ. Pediatric palliative care. Curr Oncol Rep. 2007 Nov;9(6):437-9. Review.

Weidner NJ. The evolution of pediatric palliative medicine and its integration with anesthesia. Int Anesthesiol Clin. 2006 Winter;44(1):109-18. Review.

Weidner NJ. Developing an interdisciplinary palliative care plan for the patient with muscular dystrophy. Pediatr Ann. 2005 Jul;34(7):546-52. Review.

Researchers

Paul R. Andreassen, PhD Member, Division of Experimental Hematology & Cancer Biology 513-636-0499 paul.andreassen@cchmc.org

High Res

Paul R. Andreassen, PhD

Member, Division of Experimental Hematology & Cancer Biology

Academic Affiliations

Associate Professor, UC Department of Pediatrics

Phone 513-636-0499

Fax 513-636-3549

Email paul.andreassen@cchmc.org

Show All

Visit the Andreassen Lab.

Clinical

Fanconi anemia; breast cancer susceptibility; genome instability; DNA damage responses; replication stress; relationship of DNA repair and chromatin; mitosis; cell biology

Research

Biography

Paul Andreassen completed his PhD in Experimental Pathology from the University of Washington (Seattle, WA) while working at the Fred Hutchinson Cancer Research Center (Seattle) and the Institut de Biologie Structurale (Grenoble, France). Dr. Andreassen then completed a research fellowship at the Dana-Farber Cancer Institute (Boston, MA) before moving to Cincinnati Children’s Hospital Medical Center in 2004.

BS: Willamette University, Salem, Oregon, 1984.

PhD: University of Washington, Seattle, Washington, 1995.

Mohammad Azam, PhD Member, Division of Experimental Hematology & Cancer Biology 513-803-1413 mohammad.azam@cchmc.org

Jose A. Cancelas Perez, MD, PhD Director, Research Division and Medical Director for Cell Therapies, Hoxworth Blood Center 513-558-1324 jose.cancelas@uc.edu

High Res

Jose A. Cancelas Perez, MD, PhD

Director, Research Division and Medical Director for Cell Therapies, Hoxworth Blood Center

Deputy Director, Hoxworth Blood Center

Leader, Stem Cell Program

Incumbent, Beatrice C. Lampkin Endowment for Stem Cell and Hematotherapy

Academic Affiliations

Professor, UC Department of Pediatrics

Phone 513-558-1324

Fax 513-558-1522

Email jose.cancelas@uc.edu

Show All

Clinical

Hematopoietic stem cell proliferation and differentiation

Research

Visit the Cancelas Lab.

MD: Autonomous University of Madrid, Spain, 1989.

Residency: Hematology and Hematotherapy, University of Alcala de Henares, Madrid, Spain, 1993.

PhD: Faculty of Medicine, University of Alcala de Henares, Madrid, Spain, 1996.

Grants

Progenitor Cell Biology Consortium Administrative Coordinating Center, NHLBI/ Subaward through Univ. Maryland. Co-Director. (Cincinnati Cell Char Core). Sep 2010 – Aug 2016. #U01 HL099997.

Stella M. Davies, MBBS, PhD, MRCP Director, Division of Bone Marrow Transplantation and Immune Deficiency 513-636-1371 stella.davies@cchmc.org

High Res

Stella M. Davies, MBBS, PhD, MRCP

Director, Division of Bone Marrow Transplantation and Immune Deficiency

Institute Co-Director, Cancer and Blood Diseases Institute

Jacob G. Schmidlapp Endowed Chair

Academic Affiliations

Professor, UC Department of Pediatrics

Phone 513-636-1371

Fax 513-803-1969

Email stella.davies@cchmc.org

Show All

Visit the Davies Lab.

Biography

Dr. Davies has been elected by peers for inclusion in the Best Doctors in America List.

MBBS: University of Newcastle-Upon-Tyne, England, 1981.

Clinical and Fellowship Training: The Royal Victoria Infirmary, Newcastle General Hospital and Great Ormond St. Hospital, 1981 to 1985.

PhD: University of Newcastle-Upon-Tyne, England, 1989.

Pediatric Fellowship: University of Minnesota, Minneapolis, MN, 1989 to 1993.

Myers KC, Davies SM. Hematopoietic stem cell transplantation for bone marrow failure syndromes in children. Biol Blood Marrow Transplant. 2009 Mar;15(3):279-92. Review.

Hartmut Geiger, PhD Director, Comprehensive Mouse and Cancer Core 513-636-1338 hartmut.geiger@cchmc.org

H. Leighton (Lee) Grimes, PhD Director, Cancer Pathology Program, Division of Experimental Hematology & Division of Pathology 513-636-6089 lee.grimes@cchmc.org

High Res

H. Leighton (Lee) Grimes, PhD

Director, Cancer Pathology Program, Division of Experimental Hematology & Division of Pathology

Co-Leader, Program in Hematologic Malignancies of Cincinnati Children's Hospital Medical Center, Cancer and Blood Diseases Institute

Academic Affiliations

Professor, UC Department of Pediatrics

Phone 513-636-6089

Fax 513-636-5355

Email lee.grimes@cchmc.org

Show All

Acute myelogenous leukemia; T-cell acute lymphoblastic leuekemia; severe congenital neutropenia; hematopoiesis; myelopoiesis; lineage decision; transcription factor

Visit the Grimes Lab.

Biography

Dr. Grimes has a broad background in hematopoiesis, molecular biology, and molecular oncology including modeling of hematopoiesis, myelopoiesis and leukemia. His work on the Growth factor independent-1 (Gfi1) transcriptional repressor protein has spanned the initial identification of Gfi1 in a model of leukemia and the role of Gfi1 in normal myeloid biology, to the identification of GFI1 mutations in patients with severe congenital neutropenia (SCN) and non-immune chronic idiopathic neutropenia of adults (NI-CINA). His work utilizes Gfi1 as a molecular probe to understand both normal myeloid development and innate immune action, as well as marrow failure and transformation.

PhD: Immunology and Molecular Pathology, University of Florida, Gainesville, FL.

Postdoctoral Fellow: Fox Chase Cancer Center.

Olsson A, Venkatasubramanian M, Chaudhri VK, Aronow BJ, Salomonis N, Singh H, Grimes HL. Single-cell analysis of mixed-lineage states leading to a binary cell fate choice. Nature. 2016 Aug 31.

Meyer SE, Qin T, Muench DE, Masuda K, Venkatasubramanian M, Orr E, Suarez L, Gore SD, Delwel R, Paietta E, Tallman MS, Fernandez H, Melnick A, Le Beau MM, Kogan S, Salomonis N, Figueroa ME, Grimes HL. DNMT3A Haploinsufficiency Transforms FLT3ITD Myeloproliferative Disease into a Rapid, Spontaneous, and Fully Penetrant Acute Myeloid Leukemia. Cancer Discovery. 2016; May;6(5):501-15.

Muench DE, Grimes HL. Transcriptional Control of Stem and Progenitor Potential. Curr Stem Cell Rep. 2015 Sep;1(3):139-150.

Nayak RC, Trump LR, Aronow BJ, Myers K, Mehta P, Kalfa T, Wellendorf AM, Valencia CA, Paddison PJ, Horwitz MS, Grimes HL#, Lutzko C#, Cancelas JA#. Pathogenesis of ELANE-mutant severe neutropenia revealed by induced pluripotent stem cells. J Clin Invest. 2015 Aug 3;125(8):3103-16. # shared corresponding author.

Cumaraswamy AA, Lewis AM, Geletu M, Todic A, Diaz DB, Cheng XR, Brown CE, Laister RC, Muench D, Kerman K, Grimes HL, Minden MD, Gunning PT. Nanomolar-Potency Small Molecule Inhibitor of STAT5 Protein. ACS Med Chem Lett. 2014 Sep 19;5(11):1202-1206.

Velu CS, Chaubey A, Phelan JD, Horman SR, Wunderlich M, Guzman ML, Jegga AG, Zeleznik-Le NJ, Chen J, Mulloy JC, Cancelas JA, Jordan CT, Aronow BJ, Marcucci G, Bhat B, Gebelein B, Grimes HL. Therapeutic antagonists of microRNAs deplete leukemia-initiating cell activity. J Clin Invest. 2014 Jan;124(1):222-36.

Phelan JD, Saba AI, Olsson A, Zeng H, Kosan C, Messer MS, Hildeman D, Aronow B, Möröy T, Grimes HL. Growth factor independent-1 maintains Notch1-dependent transcriptional programming of lymphoid precursors. PLoS Genetics. 2013;9(9):e1003713.

Khandanpour C*, Phelan JD*, Vassen L, Schutte J, Chen R, Horman SR, Gaudreau MC, Krongold J, Zhu J, Paul WE, Duhrsen U, Gottgens B, Grimes HL# Moroy T#. Growth factor independence 1 (Gfi1) antagonizes a p53-induced DNA damage response pathway in lymphoblastic leukemia. Cancer Cell. 2013 Feb 11;23(2):200-14. * equal first author, # shared corresponding author.

Grants

Developing Novel STAT5 Protein Inhibitors for treatment of leukemias. Principal Investigator. National Cancer Institute. Sept 2014–Sept 2017. R21CA186945.

MicroRNA in Acute Myeloid Leukemia. Principal Investigator. National Cancer Institute. Jul 2011–Apr 2017. R01CA159845.

Mechanisms of granulocyte homeostasis. Principal Investigator. National Heart Lung and Blood Institute. Sept 2015–Sept 2019. R01HL122661.

A rapid spontaneous murine model of CN-AML. Principal Investigator. National Cancer Institute. Jul 2016-Jun 2019. R01CA196658.

Gang Huang, PhD Member, Division of Experimental Hematology & Cancer Biology 513-636-3214 gang.huang@cchmc.org

High Res

Gang Huang, PhD

Member, Division of Experimental Hematology & Cancer Biology

Academic Affiliations

Associate Professor, UC Department of Pathology & Laboratory Medicine

Phone 513-636-3214

Fax 513-636-3768

Email gang.huang@cchmc.org

Show All

Specialties

Research in Dr. Huang’s laboratory focuses on genetic and epigenetic regulations of blood cell normal development and leukemia. The lab first demonstrated that AML1/CBFβ (a hetero-dimer transcription factor) and mixed-lineage leukemia (MLL) protein (an enzyme which methylates lysine 4 of histone H3 tails), form a regulatory complex, which is important for normal blood development and acts as a tumor suppressor in leukemia. Mutations in either one of these three genes account for majority of acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL) and myelodysplastic syndromes (MDS).

The lab also found that the AML1/CBFβ/MLL complex regulates another transcription factor, PU.1, through the upstream regulatory region of the PU.1 gene and that the epigenetic changes of the histone tails occurring in the PU.1 regulatory region correlate with the PU.1 expression level. PU.1 expression level changes are critical for blood cell differentiation and dysregulation of PU.1 dosages leading to leukemia.

This research will provide new insight into the interplay between genetics and epigenetics in normal blood development and leukemia. It will also help to develop generic drugs for most of the AML, ALL and MDS, which will benefit the future clinical treatments.

BS: Peking University, College of Science, Beijing, P.R. China, 1991.

MS: Inner Mongolia University, Graduate School of Science, Huhhort, P.R. China, 1994.

PhD: Kyoto University, Graduate School of Medicine, Kyoto, Japan, 2001.

Grants

Role of the Hypoxia-Inducible Factor-1alpha in Myelodysplastic Syndromes. Principal investigator. National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). March 2015-Feb 2020.

A Novel Epigenetic Circuit In Acute Leukemia. Principal investigator. National Institutes of Health (NIH), National Cancer Institute (NCI). July 2014-June 2017.

Ashish R. Kumar, MD, PhD Director, Langerhans Cell Histiocytosis Center 513-803-1631 ashish.kumar@cchmc.org

High Res

Ashish R. Kumar, MD, PhD

Director, Langerhans Cell Histiocytosis Center

Director, Hematology/Oncology Fellowship Program

Academic Affiliations

Associate Professor, UC Department of Pediatrics

Phone 513-803-1631

Fax 513-636-3549

Email ashish.kumar@cchmc.org

Show All

Clinical

Childhood cancer and blood disorders; immune deficiency

Research

Leukemia biology; cancer biology

Visit the Kumar Lab.

Biography

Visit the HLH Center of Excellence.

Dr. Kumar received his medical degree from L.T.M. Medical College, Mumbai, India, his PhD in anatomy and cell biology from the University of Iowa, pediatric residency training at the Mayo Clinic and fellowship in pediatric hematology / oncology / BMT at the University of Minnesota. He was appointed to the faculty of the University of Minnesota in the Department of Pediatrics where he was a member of the programs in pediatric leukemia and global pediatrics. He is currently an associate professor of pediatrics in the Division of Bone Marrow Transplantation and Immune Deficiency at Cincinnati Children's within the University of Cincinnati College of Medicine. Dr. Kumar’s laboratory is engaged in researching the biology of infant leukemia. Discoveries made in his laboratory have significantly enhanced the current understanding of leukemia. Dr. Kumar is also active in education. He has delivered invited lectures and grand round presentations on various topics.

Learn more about the 700 Miles to Hope Bike Ride.

Dr. Kumar has been elected by peers for inclusion in the Best Doctors in America List.

MD: LTM Medical College, Mumbai, India.

Residency: Mayo Clinic, Rochester, MN.

Fellowship: University of Minnesota, Minneapolis, MN.

PhD: University of Iowa, Iowa City, IA.

Certification: General Pediatrics; Pediatric Hematology/Oncology Subspecialty.

Licenses: State of Ohio; State of Minnesota.

Grants

Role of MEIS1 in hematopoiesis and hematopoietic transformation. Principal Investigator. National Institutes of Health/National Heart, Lung, and Blood Institute. Jul 2012-Jun 2017.

Novel therapeutics of targeting mTOR pathway in T-cell leukemia. Co-investigator. National Institutes of Health/National Cancer Institute. Jul 2015-Jun 2017.

Ruhikanta A. Meetei, PhD Member, Division of Experimental Hematology & Cancer Biology 513-636-1768 ruhikanta.meetei@cchmc.org

James C. Mulloy, PhD Co-Leader, Hematological Malignancy Program 513-636-1844 james.mulloy@cchmc.org

High Res

James C. Mulloy, PhD

Co-Leader, Hematological Malignancy Program

Academic Affiliations

Professor, UC Department of Pediatrics

Phone 513-636-1844

Fax 513-636-3768

Email james.mulloy@cchmc.org

Show All

Visit the Mulloy Lab.

BA: St. Anselm College, Manchester, NH, 1986.

MS: Rutgers University-University of Medicine and Dentistry, New Brunswick, NJ, 1989.

PhD: Rutgers University-University of Medicine and Dentistry, New Brunswick, NJ, 1992.

Grants

Conferring in vivo metabolic resistance to a highly selective anti-AML agent. Co-Investigator. National Institutes of Health/National Cancer Institute. May 2014-Apr 2017.

Rapid Suppression of Food Allergy with Anti-Fc Epsilon Rl Alpha Antibody. Co-Investigator. Food Allergy Research & Education Inc. Apr 2014-Mar 2017.

Suppression of IgE-Mediated Disease by Polyclonal Rapid Desensitization. Co-Investigator. National Institutes of Health/National Institute of Allergy and Infectious Diseases. Jul 2014-Jun 2019.

A new Hydrogen Peroxide-activated Agent that Selectively. Co-Principal Investigator. Center for Clinical and Translational Science and Training. Jul 2015-Jun 2016.

Yi Zheng, PhD Director, Experimental Hematology and Cancer Biology 513-636-0595 yi.zheng@cchmc.org

High Res

Yi Zheng, PhD

Director, Experimental Hematology and Cancer Biology

Institute Co-Director, Cancer and Blood Diseases Institute

Katherine Stewart Waters Endowed Chair

Academic Affiliations

Professor, UC Department of Pediatrics

Phone 513-636-0595

Fax 513-636-3768

Email yi.zheng@cchmc.org

Show All

Using transgenic and gene targeted mouse models to study the physiological and pathological roles of Rho GTPases and their regulators in hematopoiesis, neurogenesis, lung cancer development and small intestinal stem cell regulations mechanism based, rational design of small molecule inhibitors targeting Rho GTPase signaling modules and pathologic functions in cancer and blood diseases; mouse model studies of mTor signaling function in hematopoietic stem cells and small intestinal stem cells.

Visit the Zheng Lab.

BS: Tsinghua University, Beijing, China, 1986.

MS: Cornell University, Ithaca, NY, 1988.

PhD: Cornell University, Ithaca, NY, 1991.

Postdoctoral Fellow: Cornell University, Ithaca, NY, 1995.

View All PubMed Publications

Kesarwani M, Huber E, Kincaid Z, Evelyn CR, Biesiada J, Rance M, Thapa MB, Shah NP, Meller J, Zheng Y, Azam M. Targeting substrate-site in Jak2 kinase prevents emergence of genetic resistance. Sci Report. 2015. In press.

Konstantinidis DG, Giger KM, Risinger M, Pushkaran S, Zhou P, Dexheimer P, Yerneni S, Andreassen P, Klingmüller U, Palis J, Zheng Y, Kalfa TA. Cytokinesis failure in RhoA-deficient mouse erythroblasts involves actomyosin and midbody dysregulation and triggers p53 activation. Blood. 2015 Jul 30. [Epub ahead of print]

Barry DM, Xu K, Meadows SM, Zheng Y, Norden PR, Davis GE, Cleaver O. Cdc42 is required for cytoskeletal support of endothelial cell adhesion during blood vessel formation. Development. 2015 Aug 7. [Epub ahead of print]

Yang JQ, Kalim KW, Li Y, Zhang S, Hinge A, Filippi MD, Zheng Y, Guo F. RhoA orchestrates glycolysis for TH2 cell differentiation and allergic airway inflammation. J Allergy Clin Immunol. 2015 Jun 19. [Epub ahead of print]

Lin Y, Zheng Y. Approaches for targeting Rho GTPases in cancer drug discovery. Expert Opin Drug Discov. 2015 Sep;10(9):991-1010.

Zandvakili I, Davis AK, Hu G, Zheng Y. Loss of RhoA exacerbates, rather than dampens, oncogenic K-Ras induced lung adenoma formation in mice. PLoS One. 2015 Jun 1;10(6):e0127923.

Evelyn CR, Biesiada J, Duan X, Tang H, Shang X, Nelson S, Seibel WL, Meller J, Zheng Y. Combined rational design and a high throughput screening platform for identifying chemical inhibitors of a Ras-activating enzyme. J Biol Chem. 2015 May 15;290(20):12879-98.

Mikelis CM, Simaan M, Ando K, Fukuhara S, Sakurai A, Amornphimoltham P, Masedunskas A, Weigert R, Chavakis T, Adams RH, Offermanns S, Mochizuki N, Zheng Y, Gutkind JS. RhoA and ROCK mediate histamine-induced vascular leakage and anaphylactic shock. Nat Commun. 2015 Apr 10;6:6725.

Li J, Zhang L, Chen Z, Xie M, Huang L, Xue J, Liu Y, Liu N, Guo F, Zheng Y, Kong J, Zhang L. Cocaine activates Rac1 to control structural and behavioral plasticity in caudate putamen. Neurobiol Dis. 2015 Mar;75:159-76.

Chang KH, Nayak RC, Roy S, Perumbeti A, Wellendorf AM, Bezold KY, Pirman M, Hill SE, Starnes J, Loberg A, Zhou X, Inagami T, Zheng Y, Malik P, Cancelas JA. Vasculopathy-associated hyperangiotensinemia mobilizes haematopoietic stem cells/progenitors through endothelial AT₂R and cytoskeletal dysregulation. Nat Commun. 2015 Jan 9;6:5914.

Grants